Low-dose lithium studied for potential Alzheimer’s prevention

Animal research has indicated that lithium orotate, a dietary supplement form of the mood‑stabilizing element, may delay the onset of dementia‑related pathology in rodent models. The findings, published in several pre‑clinical studies, showed reduced neuroinflammation and preservation of memory performance when the compound was administered at low doses. Building on this evidence, a multi‑center, double‑blind human trial is slated to begin later this year, enrolling participants with mild cognitive impairment to assess whether the same neuroprotective effects can be observed in people. The study will compare lithium orotate against a placebo over a twelve‑month period, measuring cognitive scores, brain imaging markers, and safety outcomes.

Columnist Alice Klein has examined the potential advantages and risks of lithium orotate as it moves toward clinical testing. She notes that, unlike prescription lithium carbonate, the orotate salt is marketed at lower concentrations, which could lessen the likelihood of side effects such as tremor, thyroid disruption, or renal impairment. However, Klein cautions that the supplement’s unregulated status means dosage consistency and long‑term safety remain uncertain, and that self‑medication without medical supervision could pose health hazards. The upcoming trial will provide the first rigorous data on efficacy and tolerability, determining whether lithium orotate can be considered a viable preventive strategy for dementia.